Taissa Borges Bourguignon
Research Subjects
Research Interests
Taissa Borges Bourguignon has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Lorenza Silveira Arruda
School of Sciences of Santa Casa de Misericórdia de Vitoria, Vitória, ES, Brasil
1 shared publication - Luiz Fernando Machado Barbosa
Cardiology, Hospital Santa Casa de Misericórdia de Vitória, Vitória, BRA
1 shared publication - Luíza Dias Torres
School of Sciences of Santa Casa de Misericórdia de Vitoria, Vitória, ES, Brasil
1 shared publication - Osmar Calil
Cardiology, Hospital Santa Casa de Misericórdia de Vitória, Vitória, BRA
1 shared publication - Renato Giestas Serpa
School of Sciences of Santa Casa de Misericórdia de Vitoria, Vitória, ES, Brasil
1 shared publication - Roberto Ramos Barbosa
Cardiology, Hospital Santa Casa de Misericórdia de Vitória, Vitória, BRA
1 shared publication
Latest Publications
- Open Access
- 1 August 2018
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 64 (8) , 745-754
Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers
SUMMARY OBJECTIVES This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients – 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.
- 1 August 2018
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 64 (8) , 745-754
Open AccessAnthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers
SUMMARY OBJECTIVES This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients – 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.